ERBB2 and triple-negative breast carcinoma: Therefore, identifying the metastatic lymph nodes in the clipped node among 222 patients altered the systemic treatment in only two patients (0.9%) with ypN+ triple-negative breast cancer and HER2-positive disease who received Xeloda (n=1) or TDM-1 (n=1) as adjuvant treatment, respectively.